Adding modified herpes virus to immunotherapy shows promise for treating advanced melanoma

FINDINGSIn a two-year study at UCLA, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug pembrolizumab with a herpes virus called talimogene laherpareovec, or T-VEC. Researchers led by Dr. Antoni Ribas found that the treatment ’s side effects were manageable, and comparable to side effects for people who took either pembrolizumab or T-VEC as a standalone treatment.BACKGROUNDUCLA scientists are testing the combination of pembrolizumab (marketed as Keytruda) and T-VEC (marketed as Imlygic) as a treatment option for people with advanced melanoma that doesn ’t fully respond to either treatment separately.T-VEC is a genetically modified version of the herpes simplex virus that causes cold sores, but is safe to use. T-VEC has already been approved for the treatment of melanoma and it works both by directly killing cancer cells and using a protein that attracts immune cells into the cancers. Pembrolizumab has become a standard-of-care treatment for advanced melanoma, and it is also being used to treat non –small-cell lung cancer, cancers of the head, neck, kidney and bladder, and Hodgkin’s disease. It works by taking the “brakes” off of the body’s immune system, enabling it to attack cancer.According to Ribas, people whose melanoma does not respond to pembrolizumab often lack a type of T cell called CD8+ in their tumors; the lack of CD8+ cells seems to prevent immun...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news

Related Links:

ConclusionAccording to the study results, ginseng can be potentially used for cutaneous carcinoma as a chemopreventive agent by enhancing cell-mediated immunity and maintaining redox homeostasis with multiple components, targets and links.
Source: Journal of Ginseng Research - Category: Complementary Medicine Source Type: research
This study aimed to assess survival after TARE and to identify potential prognostic factors in this patient population. METHODS: Patients with unresectable and chemorefractory CRCLM treated with TARE at our institution between February 2006 and September 2015 were included in the study. Survival rate, hepatic tumor response, and potential prognostic factors were analyzed. RESULTS: In the 43 study patients, the mean follow-up was 15.0 ± 14.2 months, with a median survival of 13.0 months and 1-, 2-, 3-, 4-, and 5-year survival rates of 52.1%, 24.9%, 21.4%, 21.4%, and 7.1%, respectively. The mean activity of yt...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Conclusion: PD-L1 expression in microenvironment predicted better PFS. The combination of EGFR inhibitors and ICB could help deepening the knowledge about the interrelations between the EGFR and PD-1/PD-L1 pathways.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 20 May 2019Source: Journal of Geriatric OncologyAuthor(s): Francesco Cuccia, Gianluca Mortellaro, Rosario Mazzola, Alessandra Donofrio, Vito Valenti, Antonella Tripoli, Domenica Matranga, Antonio Lo Casto, Giuseppe Failla, Giuseppe Di Miceli, Giuseppe FerreraAbstractObjectivesTo investigate whether assessment with two geriatric screening tools shows a correlation with clinical outcomes of patients aged 65 years or more, with early-stage Non-Small Cell Lung Cancer (es-NSCLC) treated with hypofractionated stereotactic radiotherapy.MethodsFrom March 2014 to June 2018 we retrospectively eva...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsTo engage frail older adults with CRC in preoperative exercise programs information on exercise should improve. Exercise programs should be easily accessible and take personal preferences, needs and abilities into account.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 20 May 2019Source: Journal of Geriatric OncologyAuthor(s): Elizabeth J. Siembida, Erin E. Kent, Keith M. Bellizzi, Ashley Wilder SmithAbstractObjectivesPhysical activity (PA) promotes physical functioning and health-related quality of life in older survivors of cancer. Using a population-based sample of Medicare Advantage beneficiaries, we aimed to characterize the survivors who reported discussing PA with their healthcare provider.Materials and MethodsData from the Surveillance, Epidemiology, and End Results (SEER) cancer registries was linked with the 2008–2014 Medicare Health Out...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Date: Tuesday, 05 28, 2019; Speaker: Dr. Thuy Ngo, Research Assistant Professor, Oregon Health and Science University; Building 29B; 1H10
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Wednesday, 06 05, 2019; Speaker: Dana Pe'er, Sloan Kettering Institute; Nancy Allbritton, University of North Carolina at Chapel Hill; Steven Schiff, Pennsylvania State University; Denise Montell, University of California, Santa Barbara; Wendell Lim, University of California, San Francisco; Sanjay Jain, Johns Hopkins University; Christine Hendon, Columbia University; Ramsey Badawi, University of California, Davis; Deepika Mohan, University of Pittsburgh; Alexander Gimelbrant, Dana-Farber Cancer Institute; Amy Palmer, University of Colorado; Gabriel Lander, The Scripps Research Institute; Michael Angelo, Stanford Univ...
Source: NIH Calendar of Events - Category: American Health Source Type: events
InterveXion Therapeutics of Little Rock, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, announced Monday the appointment of Keith Ward, Ph.D., to president and CEO.
Source: Arkansas Business - Health Care - Category: American Health Source Type: news
[THE OFFICIAL MANUAL BOOK ON ALLERGEN-IMMUNOTHERAPY IN HOUSE-DUST-MITE ALLERGY]. Arerugi. 2019;68(3):146-150 Authors: Nagata M PMID: 31105110 [PubMed - in process]
Source: Arerugi - Category: Allergy & Immunology Authors: Tags: Arerugi Source Type: research
More News: Allergy & Immunology | Bladder Cancer | Cancer | Cancer & Oncology | Clinical Trials | Cold Sores | Colon Cancer | Colorectal Cancer | Genetics | Hematology | Herpes | Immunotherapy | Lung Cancer | Melanoma | Merck | Skin Cancer | Study | Urology & Nephrology